SEP 11, 2026 · PHASE 2 TRIAL
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
ClinicalTrials.gov
This is a Phase 2 trial registration with no results reported; it describes a planned study of an investigational drug in combination therapy for extensive-stage SCLC, addressing dose optimization and safety.
Reported
Estimated enrollment180
PhasePHASE 2
Primary outcome measure 1Number of Participants with Adverse Events,…